Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths

Luciana M.Martel Duguech, Richard S. Legro

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Polycystic ovary syndrome (PCOS) is a complex disorder which interacts with other genetic and environmental factors to cause dysregulation of steroidogenesis and anovulation as well as insulin resistance. Treatments which address the long-term effects of this unique combination of reproductive and metabolic dysfunction are needed. Over the past decade, new insights into the genetic factors of PCOS and biotechnological advances have led to potential treatments for women with PCOS. These treatments include both new potent pharmaceutical compounds and repurposed drugs which target different steps in metabolic-reproductive pathways to improve long-term health of women with PCOS. These new therapies target key enzymes involved in steroidogenesis, regulatory pathways of gonadotropin secretion, or lower oxidative stress. We review in this article the current common treatments of PCOS, recent developments in the field, and current information on the mode of action, efficacy, and safety of emerging therapeutic compounds.

Original languageEnglish (US)
Pages (from-to)326-343
Number of pages18
JournalSeminars in reproductive medicine
Issue number4
StatePublished - Jul 1 2017

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Endocrinology
  • Obstetrics and Gynecology
  • Physiology (medical)


Dive into the research topics of 'Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths'. Together they form a unique fingerprint.

Cite this